[Activity of an ampicillin/sulbactam combination in respiratory infections].

Abstract

The combination of sulbactam (S) plus ampicillin (A) extends the activity of ampicillin (Amp) against beta-lactamase producing strains. This combination is therefore useful in many clinical situations including LRTI. A clinical trial was carried out to evaluate the clinical and bacteriological efficacy of S-Amp in LRTI in comparison with Amp alone. Concerning clinical outcome the results were satisfactory in 83.3% of cases for S-Amp group and 82.3% of cases for Amp group. Pathogen eradication was achieved in 87.5% and 70.5% of cases respectively for the S-Amp and Amp group.

• Authors: P Mangiarotti, G Manara, G Grassi, G Gialdroni Grassi
• Journal: Giornale italiano di chemioterapia (G Ital Chemioter) 1989 Jan-Dec Vol. 36 Issue 1-3 Pg. 39-44 ISSN: 0017-0445 [Print] Italy
• Vernacular Title: Attività dell'associazione ampicillina/sulbactam nelle infezioni respiratorie.
• PMID: 2488911 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Ampicillin
• Sulbactam

Topics

• Adult
• Aged
• Aged, 80 and over
• Ampicillin (administration & dosage, therapeutic use)
• Bacterial Infections (drug therapy)
• Drug Therapy, Combination (therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Respiratory Tract Infections (drug therapy)
• Sulbactam (administration & dosage, therapeutic use)